JP2022527646A5 - - Google Patents

Info

Publication number
JP2022527646A5
JP2022527646A5 JP2021560416A JP2021560416A JP2022527646A5 JP 2022527646 A5 JP2022527646 A5 JP 2022527646A5 JP 2021560416 A JP2021560416 A JP 2021560416A JP 2021560416 A JP2021560416 A JP 2021560416A JP 2022527646 A5 JP2022527646 A5 JP 2022527646A5
Authority
JP
Japan
Prior art keywords
composition according
progression
disease
reduce
inhibit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021560416A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527646A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/026721 external-priority patent/WO2020206354A1/en
Publication of JP2022527646A publication Critical patent/JP2022527646A/ja
Publication of JP2022527646A5 publication Critical patent/JP2022527646A5/ja
Priority to JP2025060435A priority Critical patent/JP2025096316A/ja
Withdrawn legal-status Critical Current

Links

JP2021560416A 2019-04-05 2020-04-03 抗体によって標的化されたファゴサイトーシスにより疾患原因物質を枯渇させる方法 Withdrawn JP2022527646A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025060435A JP2025096316A (ja) 2019-04-05 2025-04-01 抗体によって標的化されたファゴサイトーシスにより疾患原因物質を枯渇させる方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962830139P 2019-04-05 2019-04-05
US62/830,139 2019-04-05
PCT/US2020/026721 WO2020206354A1 (en) 2019-04-05 2020-04-03 Methods of depleting disease causing agents via antibody targeted phagocytosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025060435A Division JP2025096316A (ja) 2019-04-05 2025-04-01 抗体によって標的化されたファゴサイトーシスにより疾患原因物質を枯渇させる方法

Publications (2)

Publication Number Publication Date
JP2022527646A JP2022527646A (ja) 2022-06-02
JP2022527646A5 true JP2022527646A5 (cg-RX-API-DMAC7.html) 2023-04-06

Family

ID=72667025

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021560416A Withdrawn JP2022527646A (ja) 2019-04-05 2020-04-03 抗体によって標的化されたファゴサイトーシスにより疾患原因物質を枯渇させる方法
JP2025060435A Pending JP2025096316A (ja) 2019-04-05 2025-04-01 抗体によって標的化されたファゴサイトーシスにより疾患原因物質を枯渇させる方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025060435A Pending JP2025096316A (ja) 2019-04-05 2025-04-01 抗体によって標的化されたファゴサイトーシスにより疾患原因物質を枯渇させる方法

Country Status (12)

Country Link
US (2) US20220169737A1 (cg-RX-API-DMAC7.html)
EP (1) EP3947467A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022527646A (cg-RX-API-DMAC7.html)
KR (1) KR20220031995A (cg-RX-API-DMAC7.html)
CN (1) CN114502585A (cg-RX-API-DMAC7.html)
AU (1) AU2020253621A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021019950A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136272A1 (cg-RX-API-DMAC7.html)
IL (1) IL286967A (cg-RX-API-DMAC7.html)
MX (1) MX2021012035A (cg-RX-API-DMAC7.html)
SG (1) SG11202110663UA (cg-RX-API-DMAC7.html)
WO (1) WO2020206354A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019000071A2 (pt) 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc conjugados adjuvantes de anticorpo
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
IL297782A (en) 2020-05-01 2022-12-01 Bolt Biotherapeutics Inc Anti-dectin-2 antibodies
EP4225373A4 (en) 2020-10-07 2025-01-08 Dren Bio, Inc. ANTI-DECTIN-1 ANTIBODIES AND METHODS OF USE THEREOF
KR20240170833A (ko) * 2022-04-04 2024-12-04 드렌 바이오, 인크. 덱틴-1 및 cd20에 결합하는 다중특이성 결합 단백질 및 이의 사용 방법
KR20250006353A (ko) * 2022-04-04 2025-01-10 드렌 바이오, 인크. 항-덱틴-1 항체 및 이의 사용 방법
AU2024316588A1 (en) * 2023-07-31 2026-01-29 Dren Bio Management, Inc. Multispecific binding proteins that bind dectin-1 and trop-2 and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI423985B (zh) * 2007-02-23 2014-01-21 貝勒研究協會 利用dectin-1活化人類抗原呈現細胞之醫療應用
US20120244155A1 (en) * 2011-03-22 2012-09-27 Baylor Research Institute Dendritic Cells (DCs) Targeting for Tuberculosis (TB) Vaccine
WO2018176159A1 (en) * 2017-03-31 2018-10-04 Zymeworks Inc. Tumor antigen presentation inducer constructs and uses thereof
TW201904588A (zh) * 2017-06-25 2019-02-01 美商西雅圖免疫公司 引導及導航控制蛋白質之製造及使用方法
CN112567026B (zh) * 2018-07-19 2024-08-23 昂科霍斯特公司 Il-31改善用于癌症的基于巨噬细胞的过继性细胞疗法的功效
SG11202100555PA (en) * 2018-07-27 2021-02-25 Alector Llc Anti-siglec-5 antibodies and methods of use thereof

Similar Documents

Publication Publication Date Title
JP7572146B2 (ja) グリコシル化免疫チェックポイントタンパク質に特異的に結合する抗体を選択する方法
JP2020513791A5 (cg-RX-API-DMAC7.html)
JP2020007318A5 (cg-RX-API-DMAC7.html)
JP2021514973A5 (cg-RX-API-DMAC7.html)
WO2006121852A3 (en) Anti-cd19 antibody therapy for autoimmune disease
JP2011207882A5 (cg-RX-API-DMAC7.html)
JP2017500057A5 (cg-RX-API-DMAC7.html)
JP2015503909A5 (cg-RX-API-DMAC7.html)
WO2006089133A8 (en) Anti-cd19 antibodies and uses in oncology
JP2023540526A5 (cg-RX-API-DMAC7.html)
JP2018500014A5 (cg-RX-API-DMAC7.html)
JP2014511179A5 (cg-RX-API-DMAC7.html)
CA3018341A1 (en) Methods for reducing toxicity of a chemotherapeutic drug
JP2013227339A5 (cg-RX-API-DMAC7.html)
US9273126B2 (en) Humanized antibodies against the beta-amyloid peptide
JP2013518903A5 (cg-RX-API-DMAC7.html)
JP2014529610A5 (cg-RX-API-DMAC7.html)
JP2023540444A5 (cg-RX-API-DMAC7.html)
JP2021511387A5 (cg-RX-API-DMAC7.html)
JP2017507131A5 (cg-RX-API-DMAC7.html)
JP2014533357A5 (cg-RX-API-DMAC7.html)
IL274007B1 (en) Anti-CD3 antibody and pharmaceutical preparation containing it for the treatment of cancer
JP2023510429A5 (cg-RX-API-DMAC7.html)
JP2022500455A5 (cg-RX-API-DMAC7.html)
JP2021529776A5 (cg-RX-API-DMAC7.html)